Abhilash D. Pandya
- Reseacher; PhD
- +47 22 78 18 59
Abhilash earned his PhD in nanomedicine, focusing on innovative cancer treatments. His thesis was titled "Nanoparticles in Cancer Therapy." Additionally, he successfully defended a trial lecture on the "Pros and Cons of CAR-T Cell Therapy." Abhilash completed his master's in molecular biology in both Sweden and the USA. He brings extensive experience in histology and immunology research, having previously studied regulatory proteins in first trimester trophoblasts and other human pathophysiological tissues. Notably, he identified a novel subset of inflammatory Natural Killer cells (NK17/NK1) in patients with Multiple Sclerosis, a neurodegenerative disease.
Since joining our group in June 2016, Abhilash has been working on novel cancer therapies, specifically targeted therapy using drug-loaded nanoparticles (NPs). His research focuses on studying the toxicity, biodistribution, and treatment response of these nanoparticles in various in vivo mice tumor models. His work aims to enhance the precision and effectiveness of cancer treatments, making them more targeted and less harmful to healthy tissues. Additionally, he is investigating the immune response induced by NPs and examining the presence of immune cells within tumors.
Publications 2024
The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy
131 (10), 1656-1667
DOI 10.1038/s41416-024-02875-5, PubMed 39390250
Preclinical Efficacy of Cabazitaxel Loaded Poly(2-alkyl cyanoacrylate) Nanoparticle Variants
19, 3009-3029
DOI 10.2147/IJN.S450283, PubMed 38562610
Publications 2023
Liver X receptors induce antiproliferative effects in basal-like breast cancer
17 (10), 2041-2055
DOI 10.1002/1878-0261.13476, PubMed 37341140
Publications 2022
Corrigendum to "Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft", [Journal of Control Release, 293 (2019) 183-192]
349, 1
DOI 10.1016/j.jconrel.2022.06.040, PubMed 35792388
Publications 2021
Biodistribution of Poly(alkyl cyanoacrylate) Nanoparticles in Mice and Effect on Tumor Infiltration of Macrophages into a Patient-Derived Breast Cancer Xenograft
11 (5)
DOI 10.3390/nano11051140, PubMed 33924869
Mechanism of cellular uptake and cytotoxicity of paclitaxel loaded lipid nanocapsules in breast cancer cells
597, 120217
DOI 10.1016/j.ijpharm.2021.120217, PubMed 33486035
Publications 2020
Drug-Loaded Photosensitizer-Chitosan Nanoparticles for Combinatorial Chemo- and Photodynamic-Therapy of Cancer
21 (4), 1489-1498
DOI 10.1021/acs.biomac.0c00061, PubMed 32092254
Physicochemical Characterization, Toxicity and In Vivo Biodistribution Studies of a Discoidal, Lipid-Based Drug Delivery Vehicle: Lipodisq Nanoparticles Containing Doxorubicin
16 (4), 419-431
DOI 10.1166/jbn.2020.2911, PubMed 32970975
Publications 2019
Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy
14, 6269-6285
DOI 10.2147/IJN.S208938, PubMed 31496685
Publications 2018
Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft
293, 183-192
DOI 10.1016/j.jconrel.2018.11.029, PubMed 30529259
Publications 2016
Tube formation in the first trimester placental trophoblast cells: Differential effects of angiogenic growth factors and fatty acids
40 (6), 652-61
DOI 10.1002/cbin.10601, PubMed 26992362
Publications 2014
Expression of the T cell-specific adapter protein in human tissues
80 (3), 169-79
DOI 10.1111/sji.12199, PubMed 24910151
Publications 2011
Identification of human NK17/NK1 cells
6 (10), e26780
DOI 10.1371/journal.pone.0026780, PubMed 22039549